Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents
- 17 October 2009
- journal article
- pharmacoepidemiology and-prescription
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (2) , 199-206
Abstract
The aim of the present study was to collect and compare cases of drug-induced PML in order to contribute to the debate about the role of the underlying diseases and/or drug immunosuppression in PML occurrence.Keywords
This publication has 30 references indexed in Scilit:
- Immune-Mediated Adverse Drug ReactionsChemical Research in Toxicology, 2008
- Natalizumab: a country-based surveillance programNeurological Sciences, 2008
- Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in ItalyDrug Safety, 2008
- Database size and power to detect safety signals in pharmacovigilanceExpert Opinion on Drug Safety, 2007
- ???Extreme Duplication??? in the US FDA Adverse Events Reporting System DatabaseDrug Safety, 2007
- Review of Progressive Multifocal Leukoencephalopathy and NatalizumabThe Neurologist, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005